Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsey Sangaralingham

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Digestive Diseases and Sciences|June 4, 2021
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
Clinical and Translational Gastroenterology|July 6, 2021
Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
Annals of the American Thoracic Society|January 19, 2021
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary FibrosisTimothy M Dempsey, Stephanie Payne, Lindsey Sangaralingham, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Jeph Herrin, et al.
Inflammatory Bowel Diseases|December 16, 2020
Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
JCO Oncology Practice|October 31, 2022
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic ChemotherapyDaniel S Childs, David A Helfinstine, Lindsey Sangaralingham, et al.
Diabetes Technology & Therapeutics|August 17, 2019
Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort StudyRozalina G McCoy, Hayley J Dykhoff, Lindsey Sangaralingham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured PopulationUrshila Durani, Dennis Asante, Thorvardur Halfdanarson, et al.
JAMA Network Open|July 31, 2025
Variations in the Use of Outpatient SurgeryChi Zhang, Kristine Hanson, Lindsey Sangaralingham, et al.
BMJ Surgery, Interventions, & Health Technologies|January 20, 2022
Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technologyJoseph G Akar, James P Hummel, Xiaoxi Yao, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Digestive Diseases and Sciences|June 4, 2021
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
Clinical and Translational Gastroenterology|July 6, 2021
Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
Annals of the American Thoracic Society|January 19, 2021
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary FibrosisTimothy M Dempsey, Stephanie Payne, Lindsey Sangaralingham, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Jeph Herrin, et al.
Inflammatory Bowel Diseases|December 16, 2020
Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel DiseasesSiddharth Singh, Herbert C Heien, Lindsey Sangaralingham, et al.
JCO Oncology Practice|October 31, 2022
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic ChemotherapyDaniel S Childs, David A Helfinstine, Lindsey Sangaralingham, et al.
Diabetes Technology & Therapeutics|August 17, 2019
Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort StudyRozalina G McCoy, Hayley J Dykhoff, Lindsey Sangaralingham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured PopulationUrshila Durani, Dennis Asante, Thorvardur Halfdanarson, et al.
JAMA Network Open|July 31, 2025
Variations in the Use of Outpatient SurgeryChi Zhang, Kristine Hanson, Lindsey Sangaralingham, et al.
BMJ Surgery, Interventions, & Health Technologies|January 20, 2022
Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technologyJoseph G Akar, James P Hummel, Xiaoxi Yao, et al.
Pageof 3